With advances in fast chromatography techniques, and highly sensitive and selective detection methods such as mass spectrometry, high-throughput bioanalytical methods can now be easily developed. The bottleneck of the analytical process then becomes the sample preparation, which it is now realized is crucial to the robust operation of the analytical system, especially for quantitative assays. Turbulent flow liquid chromatography was developed in the late 1990s, and combines 'size exclusion' and traditional stationary phase column chemistry to separate macromolecules, such as proteins, from smaller molecules and analytes of interest in biological fluids. In this presentation, two senior scientists from Viapath at King's College Hospital, London, will describe the theory behind Thermo Scientific™ TurboFlow™ chromatography, and illustrate application of the technology using two examples from their ongoing research; (1) the detection of catecholamine-producing tumours (pheochromocytoma and paraganglioma) by analysis of metanephrines in plasma and urine, and (2) the quantification of direct oral anticoagulants (DOACs).
Key learning objectives
- Detection of (pheochromocytoma and paraganglioma) by analysis of metanephrines in plasma and urine.
- Quan/Qual analysis of direct oral anticoagulants (DOACs).
- Versatility of HRMS instrument in a clinical research environment.
- Quantitative analyses with LC-MS HRMS with respect to sensitivity, selectivity, etc.
Who should attend
Researchers and Scientists in the Life Sciences/Health Care and Core Facility Personnel who are interested in:
- Quan/Qual or relative quantifications of small molecule compounds for purpose of research into drug monitoring research.
- Analytical versatility of LC-MS HRMS.
- Theory and application of online sample preparation using Turboflow chromatography.
- Using LC-MS in the clinical research laboratory.
Lewis began work at The Medical Toxicology Unit, London, in 2003. After returning to Loughborough University to complete his undergraduate degree, he returned to work at the MTU in 2005, before undertaking a formal four-year clinical scientist training programme and MSc specialising in analytical toxicology. During this time, he moved to King’s College Hospital, London, where he now works as a registered clinical scientist in the departments of clinical biochemistry and toxicology. He is involved with research and analytical method development/validation using HPLC, and LC-MS(/MS) for a range of toxicology- and biochemistry-related analytes. He has an interest in the use of TurboFlow technology for high-throughput analysis of drugs and endogenous compounds, and has published reviews on LC-MS in analytical toxicology, the use of LC-MS in steroid analysis, LC-MS analysis of parathyroid hormone, and on TurboFlow technology, and original research articles on vitamin D metabolites, porphyrins, novel calibration approaches, and TDM of clozapine and norclozapine. He is currently studying for a PhD at the University of Leicester, developing novel mass spectrometric immunoassay (MSIA) methods for the measurement of a number of analytes, including proteins and peptides, relevant in the determination of vitamin D status in different disease populations.
David has been working at King’s College Hospital since 2009, initially as a regionally funded Trainee Clinical Scientist, completing an MSc in Clinical Biochemistry in 2011. He holds a BSc and PhD in Biochemistry, both from the University of Leeds. Since gaining registration as a Clinical Scientist with the Health and Care Professions Council, his daily work has encompassed the development and implementation of new liquid chromatography tandem mass spectrometry methods. David has a particular interest in endocrine testing, including working on the development of a serum steroid panelling service and is a member of the Association for Clinical Biochemistry and Laboratory Medicine and the Society for Endocrinology.